- ESRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $304.8 million.
- ESRX has traded 81,742 shares today.
- ESRX is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ESRX with the Ticky from Trade-Ideas. See the FREE profile for ESRX NOW at Trade-Ideas More details on ESRX: Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. ESRX has a PE ratio of 32.4. Currently there are 15 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold. The average volume for Express Scripts has been 3.7 million shares per day over the past 30 days. Express Scripts has a market cap of $59.5 billion and is part of the health care sector and health services industry. The stock has a beta of 0.88 and a short float of 2.4% with 4.92 days to cover. Shares are up 16.1% year-to-date as of the close of trading on Tuesday.
- EXPRESS SCRIPTS HOLDING CO has improved earnings per share by 44.4% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. During the past fiscal year, EXPRESS SCRIPTS HOLDING CO increased its bottom line by earning $2.31 versus $1.85 in the prior year. This year, the market expects an improvement in earnings ($4.88 versus $2.31).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 36.5% when compared to the same quarter one year prior, rising from $426.70 million to $582.30 million.
- Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, the stock's rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that the other strengths this company displays justify these higher price levels.
- The debt-to-equity ratio is somewhat low, currently at 0.73, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Even though the company has a strong debt-to-equity ratio, the quick ratio of 0.45 is very weak and demonstrates a lack of ability to pay short-term obligations.
- ESRX, with its decline in revenue, underperformed when compared the industry average of 19.9%. Since the same quarter one year prior, revenues slightly dropped by 0.5%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
- You can view the full Express Scripts Ratings Report.